On a reported annual basis, revenue rose from KRW 41.2 billion in 2022 to KRW 54.3 billion in 2023 (up 31.9% year on year) and KRW 60.3 billion in 2024 (up 11.0%), then fell to KRW 56.7 billion in 2025 (down 6.0%). Of the 2022 to 2025 years, 2024 was the largest and 2022 the smallest.
Operating results moved from an operating loss of KRW 16 billion in 2022 to operating profit of KRW 3.89 billion in 2023, which marked the turn to profit, and then to KRW 13.4 billion in 2024 (up 244.9%). The operating margin went from -38.9% in 2022 to 7.2% in 2023 and 22.2% in 2024.
In 2025 operating profit fell to KRW 1.63 billion (down 87.8%), pushing the margin down to 2.9%. Net profit attributable to controlling shareholders was KRW 3.61 billion in 2023 and KRW 14.7 billion in 2024, but in 2025 it turned into a loss of KRW 10.7 billion.
Operating cash flow in the same year was KRW 11 billion, up from KRW 2.54 billion in 2024. The quarterly pattern is more volatile.
After Q3 2025 revenue of KRW 15.7 billion and operating profit of KRW 562 million, Q4 2025 revenue fell to KRW 10.9 billion (down 30.6% from the prior quarter) and the company posted an operating loss of KRW 7.85 billion. Q1 2026 revenue was KRW 9.45 billion with an operating loss of KRW 3.44 billion.
Q2 2026 revenue rose to KRW 14.9 billion (up 57.9% from the prior quarter) and operating profit was KRW 479 million, a return to profit. Q3 2026 revenue was KRW 9.36 billion, down 40.5% from a year earlier, and the operating loss widened to KRW 6.31 billion.
In its preliminary disclosure on November 5, 2026, the company attributed the Q3 revenue decline to adjusted shipment schedules for some overseas volumes, and the wider operating loss to one-off costs, including inventory disposal and valuation losses from trial production for Fabagal process verification.
The company said deferred revenue will be reflected in Q4. The cumulative net loss attributable to controlling shareholders over the last four quarters totals KRW 16.5 billion. The company also said R&D spending equaled 41.2% of revenue in Q1 2026.